Tag: Atazanavir

First approved by the FDA in 2003, atazanavir (brand name Reyataz) is an antiretroviral medication from the protease inhibitor class used to treat human immunodeficiency virus (HIV) infection. By blocking a critical enzyme the virus needs to mature, it helps decrease the amount of HIV in the blood.

First approved by the FDA on **June 20, 2003**, atazanavir (Reyataz) marked a significant advancement in HIV treatment as the first once-daily protease inhibitor for adults. The answer to the question 'when was atazanavir FDA approved?' highlights a key moment in the evolution of antiretroviral therapy and the shift towards more convenient, patient-friendly dosing regimens.

First approved by the FDA in 2003, atazanavir revolutionized HIV treatment by offering a potent antiretroviral with a once-daily dosing regimen. This medication's impact stems directly from what is the classification of atazanavir within modern pharmacology, defining its role in managing HIV infection effectively.